ES2102815T5 - Procedimiento para la obtencion de ectodominios nativos, oligomeros, glicosilados de proteinas de membrana virales, su utilizacion, en especial como vacuna contra el vih. - Google Patents

Procedimiento para la obtencion de ectodominios nativos, oligomeros, glicosilados de proteinas de membrana virales, su utilizacion, en especial como vacuna contra el vih.

Info

Publication number
ES2102815T5
ES2102815T5 ES94904568T ES94904568T ES2102815T5 ES 2102815 T5 ES2102815 T5 ES 2102815T5 ES 94904568 T ES94904568 T ES 94904568T ES 94904568 T ES94904568 T ES 94904568T ES 2102815 T5 ES2102815 T5 ES 2102815T5
Authority
ES
Spain
Prior art keywords
protein
native
ectodomines
organization
recovered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94904568T
Other languages
English (en)
Other versions
ES2102815T3 (es
Inventor
Manfred Schawaller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6478309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2102815(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2102815T3 publication Critical patent/ES2102815T3/es
Publication of ES2102815T5 publication Critical patent/ES2102815T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN PROCEDIMIENTO PARA LA RECUPERACION DE DOMINIOS NATIVOS DE PROTEINAS DE MEMBRANAS VIRALES, EN PARTICULAR NATIVAS, ES DECIR OLIGOMEROS Y ECTODOMINIOS GLICOSILADOS DE PROTEINA SUPERFICIAL GP 160 DEL VIRUS DE INMUNODEFICIENCIA HUMANA, QUE EN EL ORGANISMO ORIGINA EL SIDA (AQUIRED IMMUNE DEFICIENCY SYNDROME) EN BASE AL VIRUS HIV (HUMAN IMMUNODEFICIENCY VIRUS), ASI COMO A LOS DOMINIOS DE PROTEINA NATIVA RECUPERADOS MEDIANTE EL PROCESO, EN PARTICULAR ECTODOMINIOS NATIVOS DE GLICOPROTEINA HIV DE ENVUELTA CUYOS MONOMEROS DISPONEN DE UNA MOVILIDAD ELECTROFORETICA DE APROXIMADAMENTE 140 KD, Y SU UTILIZACION COMO VACUNA, EN PARTICULAR COMO VACUNA CONTRA HIV. UNA SECUENCIA DE NUCLEOTIDO QUE SE CODIFICA PARA UNA SECUENCIA DE RECONOCIMIENTO DE ENZIMAS PROTEOLITICAS SE INSERTA EN UN LUGAR APROPIADO DEL EJE QUE CODIFICA LA PROTEINA PRECURSORA DE LOS DOMINIOS DE PROTEINA A SER RECUPERADOS. DESPUES DE QUE EL MUTANTE GENETICO SE EXPRESA EN CELDAS EUCARIOTICAS, SE DIGIEREN CON UNA ENZIMA APROPIADA Y SE PURIFICA ENTONCES EL DOMINO DE PROTEINA A SER RECUPERADO.
ES94904568T 1993-01-16 1994-01-12 Procedimiento para la obtencion de ectodominios nativos, oligomeros, glicosilados de proteinas de membrana virales, su utilizacion, en especial como vacuna contra el vih. Expired - Lifetime ES2102815T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4301017 1993-01-16

Publications (2)

Publication Number Publication Date
ES2102815T3 ES2102815T3 (es) 1997-08-01
ES2102815T5 true ES2102815T5 (es) 2001-11-16

Family

ID=6478309

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94904568T Expired - Lifetime ES2102815T5 (es) 1993-01-16 1994-01-12 Procedimiento para la obtencion de ectodominios nativos, oligomeros, glicosilados de proteinas de membrana virales, su utilizacion, en especial como vacuna contra el vih.

Country Status (9)

Country Link
US (1) US6140059A (es)
EP (1) EP0679187B2 (es)
JP (1) JP3658690B2 (es)
AT (1) ATE153380T1 (es)
DE (2) DE4400659C2 (es)
DK (1) DK0679187T4 (es)
ES (1) ES2102815T5 (es)
GR (1) GR3023717T3 (es)
WO (1) WO1994016081A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2781676B1 (fr) * 1998-07-31 2004-04-02 Pasteur Merieux Serums Vacc Trimere du produit d'expression du gene env de hiv
US6602705B1 (en) * 1998-12-31 2003-08-05 Chiron Corporation Expression of HIV polypeptides and production of virus-like particles
WO2000039304A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2596600A (en) 1998-12-31 2000-07-31 Chiron Corporation Modified hiv env polypeptides
WO2001019958A2 (en) * 1999-09-17 2001-03-22 Dana-Farber Cancer Institute, Inc. Stabilized soluble glycoprotein trimers
US7179468B1 (en) 2000-06-08 2007-02-20 Cornell Research Foundation, Inc. Antigen for developing neutralizing antibodies to human immunodeficiency virus
US20030198621A1 (en) * 2001-07-05 2003-10-23 Megede Jan Zur Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
AU2002316578A1 (en) * 2001-08-31 2003-03-18 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
JP2007502623A (ja) * 2003-05-09 2007-02-15 リサーチ ディベロップメント ファウンデーション 膜タンパク質におけるフリンプロテアーゼ開裂部位の挿入およびその使用法
US7358334B1 (en) 2003-11-14 2008-04-15 Jay W Chaplin B cell-targeted toxins for humoral immune response reduction and methods of use thereof
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
AU2010222930B2 (en) 2008-07-16 2013-07-25 Baylor Research Institute Antigen presenting cell targeted cancer vaccines
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
CN102770457A (zh) 2009-03-10 2012-11-07 贝勒研究院 靶向抗原呈递细胞的疫苗
CA2754862C (en) * 2009-03-10 2019-04-02 Baylor Research Institute Anti-cd40 antibodies and uses thereof
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2831294A1 (en) 2011-03-25 2012-10-04 Baylor Research Institute Compositions and methods to immunize against hepatitis c virus
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3992210A1 (en) 2014-01-13 2022-05-04 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3731874A1 (de) * 1987-09-18 1989-03-30 Schering Ag Verfahren zur herstellung von peptiden durch spezifische spaltung von gentechnisch gewonnenen fusionsproteinen mit collagenasen
IL89567A0 (en) * 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein
CA2077753C (en) 1990-03-09 2000-02-29 Nancy L. Haigwood Purified gp120 composition retaining natural conformation
FR2676071B1 (fr) * 1991-05-02 1994-11-18 Transgene Sa Nouveau variant gp160 non-clivable, soluble, de forme hybride.

Also Published As

Publication number Publication date
DK0679187T3 (da) 1997-12-08
JPH08505769A (ja) 1996-06-25
DE59402827D1 (de) 1997-06-26
ATE153380T1 (de) 1997-06-15
US6140059A (en) 2000-10-31
EP0679187A1 (de) 1995-11-02
DE4400659C2 (de) 1995-07-27
DE4400659A1 (de) 1994-07-21
EP0679187B1 (de) 1997-05-21
EP0679187B2 (de) 2001-07-04
GR3023717T3 (en) 1997-09-30
WO1994016081A1 (de) 1994-07-21
JP3658690B2 (ja) 2005-06-08
ES2102815T3 (es) 1997-08-01
DK0679187T4 (da) 2001-09-17

Similar Documents

Publication Publication Date Title
ES2102815T5 (es) Procedimiento para la obtencion de ectodominios nativos, oligomeros, glicosilados de proteinas de membrana virales, su utilizacion, en especial como vacuna contra el vih.
AR069653A2 (es) Variante de glucoamilasa original de aspergillus, una construccion de adn, un vector de expresion recombinante, una celula, un proceso para convertir almidon, uso de una variante de glucoamilasa para un proceso de la fermentacion y metodo para alterar la estabilidad termica.
EP0185444A3 (en) Cloning and expression of htlv-iii dna
DE68924162T2 (de) Stressproteine und verwendungen dafür.
BR8301918A (pt) Proteina,sequencia de dna,veiculo de expressao replicavel,microorganismo ou cultura celular,plasmideo,composicao,cultura de celulas,utilizacao de tal proteina,processo de expressao,processo para producao de um veiculo de expressao e processo para preparacao de uma proteina uroquinase
DK0909323T3 (da) Helicobacter pylori-bakterioferritin
NO975546D0 (no) Antigene gruppe B-streptokokk-type II- og type III-polysakkaridfragmenter med en 2,5-anhydro-D-mannose-terminal struktur samt en konjugatvaksine derav
DE69132902D1 (de) Methoden zur identifizierung heterofunktionaler fusionsproteine
CO4480058A1 (es) Genes codificantes y procedimiento de expresion de una nueva enzima: ftalil amidasa
BR9612422A (pt) Pseudo-partìculas virais recombinantes, composição, utilização de pseudo-partìculas, e, processo de estimulação in vitro de respostas t citotóxicas de linfócitos provenientes de indivìduos atingidos por infecções virais ou tumorais.
KR860001882A (ko) 왁진 효능이 있는 폴리펩타이드
DE60027581D1 (de) Design von immunogene
NO178870C (no) Fremgangsmåte for fremstilling av modifisert Eglin B eller C samt DNA, ekspresjonsvektor og vertsmikroorganisme
KR890008166A (ko) 융합 단백질의 선택적 분해 방법
ES2061524T3 (es) Un vector plasmidico para la expresion en bacillus y empleado para la clonacion del gen estructural que codifica la hormona de crecimiento humana y un metodo para la produccion de la hormona.
Martinez et al. The amino acid sequence of cytochrome c from Solanum tuberosum (potato)
ATE144429T1 (de) Impfstoff
GT198304126A (es) Produccion de proteinas del virus de herpes simplex
NO874391L (no) Nye gjaerekspresjonsvektorer for ifn-omega samt fremgangsmaate for fremstilling og anvendelse derav.
TH4073EX (th) รีคอมบิแนนท์ ไวรัส
FI934079A (fi) Menetelmä fuusioproteiinin valmistamiseksi
TH4073A (th) รีคอมบิแนนท์ ไวรัส
RU93058612A (ru) Клонирование и экспрессия автоантигенов декарбоксилазы глутаминовой кислоты островковых клеток человека

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 679187

Country of ref document: ES